J. Watson

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

R. Collins, G. Hankey, A. Keech, 1998, The New England journal of medicine.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus

K. Mahaffey, V. Perkovic, D. Matthews, 2018, Stroke.

Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin

G. Hankey, H. White, A. Tonkin, 2002, Journal of hypertension.

Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial

Mark Woodward, Bruce Neal, Giuseppe Mancia, 2013, PloS one.

If Time Is Brain Where Is the Improvement in Prehospital Time after Stroke?

J. Watson, Jeremy N. Pulvers, 2017, Front. Neurol..

Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation

R. Collins, P. Sandercock, M. Woodward, 2001 .

Pravastatin therapy and the risk of stroke.

P Glasziou, A M Tonkin, G. Hankey, 2000, The New England journal of medicine.